# Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy

> **NCT02979873** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 84 (actual)

## Conditions studied

- Severe Aplastic Anemia

## Interventions

- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT02979873
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-12-19
- **Primary completion:** 2025-09-04
- **Final completion:** 2030-06-30
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02979873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02979873, "Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT02979873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*